Skip to main content

Advertisement

SpringerLink
Log in

Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Seban R-D, Nemer JS, Marabelle A, Yeh R, Deutsch E, Ammari S, et al. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics. Eur J Nucl Med Mol Imaging. 2019;46:2298–310.

    Article  CAS  Google Scholar 

  2. Seban R-D, Moya-Plana A, Antonios L, Yeh R, Marabelle A, Deutsch E, et al. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4. Eur J Nucl Med Mol Imaging. 2020;47:2301–12.

    Article  CAS  Google Scholar 

  3. Seban R-D, Mezquita L, Berenbaum A, Dercle L, Botticella A, Le Pechoux C, et al. Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors. Eur J Nucl Med Mol Imaging. 2020;47:1147–57.

    Article  CAS  Google Scholar 

  4. Seban R-D, Assié J-B, Giroux-Leprieur E, Massiani M-A, Soussan M, Bonardel G, et al. Association of the metabolic score using baseline FDG-PET/CT and dNLR with immunotherapy outcomes in advanced NSCLC patients treated with first-line pembrolizumab. Cancers (Basel). 2020;12.

  5. Wong A, Callahan J, Keyaerts M, Neyns B, Mangana J, Aberle S, et al. 18F-FDG PET/CT based spleen to liver ratio associates with clinical outcome to ipilimumab in patients with metastatic melanoma. Cancer Imaging. 2020;20:36.

    Article  Google Scholar 

  6. Wong ANM, Callahan J, Beresford J, Herschtal A, Fullerton S, Milne D, et al. Spleen to liver ratio (SLR): novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. JCO. 2016;34:9523–3.

  7. Yeh R, Trager MH, Rizk EM, Finkel GG, Barker LW, Carvajal RD, et al. FLT-PET at 6 weeks predicts response assessed by CT at 12 weeks in melanoma patients treated with pembrolizumab. Clin Nucl Med. 2020;45:267–75.

    Article  Google Scholar 

  8. Schwenck J, Schörg B, Fiz F, Sonanini D, Forschner A, Eigentler T, et al. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive in vivo18F-FDG-PET. Theranostics. 2020;10:925–37.

    Article  CAS  Google Scholar 

  9. Seith F, Forschner A, Weide B, Gückel B, Schwartz M, Schwenck J, et al. Is there a link between very early changes of primary and secondary lymphoid organs in 18F-FDG-PET/MRI and treatment response to checkpoint inhibitor therapy? J Immunother Cancer. 2020;8.

  10. Schüle SC, Eigentler T, Pfannenberg C. Multiple enlarged metabolically active lymph nodes in 18F-FDG PET/CT after anti-CTLA-4 antibody therapy in metastatic melanoma-disease progression or immunologically induced side effect? Rofo. 2015;187:1036–7.

    Article  Google Scholar 

  11. Tsai KK, Pampaloni MH, Hope C, Algazi AP, Ljung B-M, Pincus L, et al. Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade. J Immunother Cancer. 2016;4:58.

    Article  Google Scholar 

  12. Nam H-Y, Kim S-J, Kim I-J, Kim B-S, Pak K, Kim K. The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance. Clin Nucl Med. 2010;35:759–63.

    Article  Google Scholar 

  13. Aktaş GE, Sarıkaya A, Demir SS. Diffusely increased splenic fluorodeoxyglucose uptake in lung cancer patients. Turk Thorac J. 2017;18:6–10.

    Article  Google Scholar 

  14. Dercle L, Seban R-D, Lazarovici J, Schwartz LH, Houot R, Ammari S, et al. 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor. J Nucl Med. 2018;59:15–24.

    Article  CAS  Google Scholar 

  15. Chen A, Mokrane F-Z, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella J-M, et al. Early 18F-FDG PET/CT response predicts survival in relapsed or refractory Hodgkin lymphoma treated with nivolumab. J Nucl Med. 2020;61:649–54.

    Article  CAS  Google Scholar 

  16. Dercle L, Ammari S, Seban R-D, Schwartz LH, Houot R, Labaied N, et al. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. Eur J Cancer. 2018;91:136–44.

    Article  CAS  Google Scholar 

  17. Dercle L, Mokrane F-Z, Schiano de Colella JM, Stamatoullas A, Morschhauser F, Brice P, et al. Unconventional immune-related phenomena observed using 18F-FDG PET/CT in Hodgkin lymphoma treated with anti PD-1 monoclonal antibodies. Eur J Nucl Med Mol Imaging. 2019;46:1391–2.

    Article  Google Scholar 

  18. Mokrane F-Z, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella J-M, et al. Performance of CT compared with 18F-FDG PET in predicting the efficacy of nivolumab in relapsed or refractory Hodgkin lymphoma. Radiology. 2020;295:651–61.

    Article  Google Scholar 

  19. Yoon H-J, Kim BS, Moon CM, Yoo J, Lee KE, Kim Y. Prognostic value of diffuse splenic FDG uptake on PET/CT in patients with gastric cancer. PLoS One. 2018;13:e0196110.

    Article  Google Scholar 

  20. Kim SY, Moon CM, Yoon H-J, Kim BS, Lim JY, Kim TO, et al. Diffuse splenic FDG uptake is predictive of clinical outcomes in patients with rectal cancer. Sci Rep. 2019;9:1313.

    Article  Google Scholar 

  21. Bang J-I, Yoon H-J, Kim BS. Clinical utility of FDG uptake within reticuloendothelial system on F-18 FDG PET/CT for prediction of tumor recurrence in breast cancer. PLoS One. 2018;13:e0208861.

    Article  Google Scholar 

  22. Şahin E, Elboğa U. Relationship between reticuloendothelial systems’ FDG uptake level and clinicopathological features in patient with invasive ductal breast cancer. Radiol Med. 2017;122:785–92.

    Article  Google Scholar 

  23. De Jaeghere EA, Laloo F, Lippens L, Van Bockstal M, De Man K, Naert E, et al. Splenic 18F-FDG uptake on baseline PET/CT is associated with oncological outcomes and tumor immune state in uterine cervical cancer. Gynecol Oncol. 2020;159:335–43.

    Article  Google Scholar 

  24. Kamran N, Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, et al. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 2018;7:e1408750.

    Article  Google Scholar 

  25. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162–74.

    Article  CAS  Google Scholar 

  26. van der Veen EL, Giesen D, Pot-de Jong L, Jorritsma-Smit A, De Vries EGE, Lub-de Hooge MN. 89Zr-pembrolizumab biodistribution is influenced by PD-1-mediated uptake in lymphoid organs. J Immunother Cancer. 2020;8.

Download references

Author information

Authors and Affiliations

  1. Department of Nuclear Medicine, Institut Curie, 92210, Saint-Cloud, France

    Romain-David Seban & Laurence Champion

  2. Laboratoire d’Imagerie Translationnelle en Oncologie, Inserm, Institut Curie, 91401, Orsay, France

    Romain-David Seban & Laurence Champion

  3. Department of Radiology, New York Presbyterian Hospital, Columbia University Medical Center, New York, NY, 10039, USA

    Lawrence H. Schwartz & Laurent Dercle

Authors
  1. Romain-David Seban
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laurence Champion
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lawrence H. Schwartz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Laurent Dercle
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Laurent Dercle.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Research involving human participants and/or animals

NA.

Informed consent

NA.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Advanced Image Analyses (Radiomics and Artificial Intelligence).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seban, RD., Champion, L., Schwartz, L.H. et al. Spleen glucose metabolism on [18F]-FDG PET/CT: a dynamic double-edged biomarker predicting outcome in cancer patients. Eur J Nucl Med Mol Imaging 48, 2309–2311 (2021). https://doi.org/10.1007/s00259-020-05126-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-020-05126-w

Search

Navigation